Dr. Cedarbaum received his B.A. and M.A. from Stanford University and his M.D. from Yale University. He completed his internship and residency in Internal Medicine at the University of Chicago Hospitals and Clinics and his Neurology residency at New York Hospital-Cornell Medical Center. He served on the faculty of Cornell Medical College and as Director of the Parkinson’s and Movement Disorders program at the Burke Rehabilitation Center in White Plains, New York and New York Hospital-Cornell Medical Center in New York City from 1983 to 1990, and subsequently has held adjunct clinical appointments at Weill-Cornell Medical College and the Mt. Sinai School of Medicine in New York City, and is currently Professor (Adjunct) of Psychiatry at Yale Medical School.
From 1990 to 2007, Dr. Cedarbaum was Vice President of Clinical Affairs at Regeneron Pharmaceuticals, leading teams conducting Phase 1 through Phase 3 studies with novel biologic agents as potential treatments for amyotrophic lateral sclerosis (Lou Gehrig’s Disease), peripheral nerve disorders, gastrointestinal motility, cancer and ophthalmological diseases. From 2007 to 2010, he was Vice President, Clinical Development at Élan Pharmaceuticals, where he led clinical development teams investigating potential small-molecule disease-modifying agents for Alzheimer’s disease. In 2010, Dr. Cedarbaum became Vice President of Clinical Research and Operations, Neuroscience and Neuromuscular Disorders at Cytokinetics, Inc., where he led clinical development of novel drugs designed to improve skeletal muscle contractility in neuromuscular disorders. From 2012-2013, Dr. Cedarbaum served as Vice President in Global Clinical Research, Neuroscience at Bristol Myers-Squib. In his role as at BMS, Dr. Cedarbaum was responsible for the clinical development of Bristol-Myers Squibb’s Neuroscience portfolio.
Dr. Cedarbaum has authored or co-authored over 90 peer-reviewed scientific publications. He is a Fellow of both the American Academy of Neurology and the American Neurological Association, and has served on the Board of Directors for the American Society for Neurological Therapeutics (ASENT). Recently Dr. Cedarbaum has been a member of the NINDS Parkinson’s Disease Biomarkers Identification Network (PDBIN) Committee and the Down Syndrome Biomarker Initiative Steering Committee, the fNIH Neuroscience Biomarkers Consortium Steering Committee, was a member of the ALS working group for the NINDS ALS Common Data Elements Project, and was the chair of the Private Partner Scientific Board (PPSB) of the Alzheimer’s disease Neuroimaging Initiative (ADNI) for 2014-15, and chair of the Industry Scientific Advisory Board (ISAB) for the Michael J. Fox foundation Parkinson Progression Markers Initiative (PPMI) for 2015-2016.